Daisho Microline Holdings Limited

Daisho Microline Holdings Limited

0567.HK
Daisho Microline Holdings LimitedHK flagHong Kong Stock Exchange
0.31
HKD
+0.00
- -
500.12MMarket Cap
Daisho Microline Holdings Limited
0567.HK
(Hong Kong Stock Exchange)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.39
0.49
0.4
0.33
0.27
0.27
0.23
0.19
0.38
1.41
1.1
0.11
0.1
0.05
0.05
0.03
Revenue per Share
-0.03
0.02
-0.1
-0.08
-0.04
0.02
-0.07
-0.06
-0.07
0.09
-0.08
-0.1
-0.03
-0.02
-0.01
-0.01
Basic EPS, GAAP
0.01
0.07
0.05
0.01
-0.01
-0.02
-0.04
-0.03
-0.06
-0.14
-0.02
0.06
-0.03
- -
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.28
0.3
0.2
0.12
0.08
0.09
0.03
-0.02
-0.09
- -
-0.08
-0.2
-0.07
-0.08
-0.08
-0.1
Book Value per Share
0.48
0.53
0.45
0.38
0.34
0.35
0.26
0.23
0.14
0.21
0.12
0.15
0.13
0.07
0.06
0.04
Tangible Book Value per Share
894
894
894
894
894
894
894
900
1,073
1,073
1,073
645
1,041
1,613
1,613
1,613
Basic Weighted Avg Shares
348
442
362
296
244
239
207
170
412
1,517
1,185
68
106
84
86
53
Sales/Revenue/Turnover
1.63
2.98
-12.43
-6.59
-11.79
-15.69
-30.91
-31.16
-8.85
-4.95
-6.01
-40.08
-23.14
-17.41
-15.7
-32.79
Operating Margin (%)
47
38
40
28
17
14
14
13
12
9
13
17
11
6
5
4
Depreciation Expense
-24
17
-92
-69
-38
14
-61
-51
-80
100
-87
-67
-29
-26
-12
-21
Net Income, GAAP
- -
18.54
- -
- -
- -
19.69
- -
- -
- -
13.74
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-6.97
3.77
-25.49
-23.15
-15.36
5.99
-29.43
-29.96
-19.44
6.62
-7.36
-98.66
-27.36
-31.06
-13.87
-39.79
Profit Margin (%)
159
182
167
156
193
197
105
97
134
170
9
25
82
56
47
25
Working Capital
2
17
19
3
- -
- -
- -
- -
98
74
2
9
- -
- -
- -
1
LT Debt
429
473
403
336
307
312
230
208
150
229
133
95
133
106
94
73
Total Equity
- -
1.97
- -
- -
- -
-5.48
- -
- -
- -
-16.93
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
5.06
- -
- -
- -
5.77
- -
- -
- -
80.97
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-16.18
6.41
-41.48
-48.22
-42.16
18.46
-112.51
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.65%
-8.67%
-22.7%
Free Cash Flow
-69.01%
-187.25%
-100.53%
Net Income, GAAP
-96.45%
-13.37%
77.93%
Sales/Revenue/Turnover
26.28%
-18.91%
-37.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
86
2025
- -
- -
- -
- -
53
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Daisho Microline Holdings Limited Daisho Microline Holdings Limited (0567.HK), an investment holding company incorporated in Bermuda in 1989 and headquartered in Chai Wan, Hong Kong, engages primarily in the manufacture and trading of printed circuit boards; the trading of petroleum and energy products and related businesses; the manufacture and trading of printing and packaging products; and investments in funds. The company operates manufacturing facilities, including a printed circuit board plant exceeding 800,000 square feet in Huizhou, Guangdong Province, People's Republic of China, and conducts business across Hong Kong, Europe, the People's Republic of China, South Korea, North America, and other international markets, targeting electronics, energy, and packaging sectors. In recent developments, through its joint venture Noricap Fund, the company pursued the acquisition of interests in Full Smart Inc., a cryptocurrency platform operator, in 2024, and announced a capital injection into a target healthcare group in March 2025—valued at RMB160 million and focused on artificial intelligence-assisted health management platforms with expert consultations, chronic disease management, and corporate health services—furthering diversification into healthcare amid cooperation agreements with hospitals, clinics, insurance firms, and a Hong Kong-listed technology conglomerate subsidiary from late 2024 to early 2025.